BridgeBio Doses First Patient in Acoramidis Heart Study
BridgeBio announced the first participant has been dosed in the ASCEND-ATTR Phase 3b/4 study evaluating acoramidis for disease regression in ATTR-CM.
Results for "ASCEND-ATTR"
1 story found
1 story found
BridgeBio announced the first participant has been dosed in the ASCEND-ATTR Phase 3b/4 study evaluating acoramidis for disease regression in ATTR-CM.